Association of Comorbid Asthma and the Efficacy of Bioabsorbable Steroid-eluting Sinus Stents Implanted After Endoscopic Sinus Surgery in Patients with Chronic Rhinosinusitis with Nasal Polyps

Abstract

Objective

To identify factors affecting the efficacy of steroid-eluting sinus stents implanted after endoscopic sinus surgery (ESS) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Methods

We performed a post-hoc analysis of a randomized self-controlled clinical trial on post-operative implantation of bioabsorbable steroid-eluting stents in patients with CRSwNP. Univariate logistic regression analysis was conducted to identify which of the following factors affect the response to post-operative stent implantation: sex, serum eosinophil levels, history of prior surgery, endoscopic scores, and comorbid conditions (asthma and allergic rhinitis). The primary outcome was the rate of post-operative intervention on day 30, and the secondary outcome was the rate of polypoid tissue formation (grades 2–3) on days 14, 30, and 90.

Results

A total of 151 patients with CRSwNP were included in the post-hoc analysis. Asthma was identified as the only risk factor for a poor response to steroid-eluting sinus stents on post-operative day 30, with an odds ratio of 23.71 (95% CI, 2.81, 200.16; P=0.004) for the need for post-operative intervention and 19 (95% CI, 2.20, 164.16; P=0.003) for moderate-to-severe polypoid tissue formation. In addition, the asthmatic group showed higher rates of post-operative intervention and polypoid tissue formation than the non-asthmatic group on post-operative day 30. Blood eosinophil levels were not identified as a risk factor for poor outcomes after stent implantation.

Conclusion

Comorbid asthma, but not blood eosinophil level, impairs the efficacy of steroid-eluting sinus stents in the short term after ESS in patients with CRSwNP.

Keywords

chronic rhinosinusitis / asthma / nasal polyps / outcome / steroid-eluting sinus stent

References

[1] FokkensWJ, LundVJ, HopkinsC, et al.. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology, 2020, 58(Suppl S29): 1-464

[2] BachertC, HanJK, DesrosiersM, et al.. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet, 2019, 394(10209): 1638-1650

[3] HanJK, BachertC, FokkensW, et al.. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med, 2021, 9(10): 1141-1153

[4] GevaertP, OmachiTA, CorrenJ, et al.. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol, 2020, 146(3): 595-605

[5] WuAC, FuhlbriggeAL, RobayoMA, et al.. Cost-Effectiveness of Biologics for Allergic Diseases. J Allergy Clin Immunol Pract, 2021, 9(3): 1107-1117.e1102

[6] LiuZ, ChenJ, ChengL, et al.. Chinese Society of Allergy and Chinese Society of Otorhinolaryngology-Head and Neck Surgery Guideline for Chronic Rhinosinusitis. Allergy Asthma Immunol Res, 2020, 12(2): 176-237

[7] WormaldPJ, BoustredRN, LeT, et al.. A prospective single-blind randomized controlled study of use of hyaluronic acid nasal packs in patients after endoscopic sinus surgery. Am J Rhinol, 2006, 20(1): 7-10

[8] KennedyDW, WrightED, GoldbergAN. Objective and subjective outcomes in surgery for chronic sinusitis. Laryngoscope, 2000, 110(3): 29-31 Pt 3

[9] LipworthBJ, JacksonCM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf, 2000, 23(1): 11-33

[10] WaljeeAK, RogersMA, LinP, et al.. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ, 2017, 357: j1415

[11] MurrAH, SmithTL, HwangPH, et al.. Safety and efficacy of a novel bioabsorbable, steroid-eluting sinus stent. Int Forum Allergy Rhinol, 2011, 1(1): 23-32

[12] LuongA, OwRA, SinghA, et al.. Safety and Effectiveness of a Bioabsorbable Steroid-Releasing Implant for the Paranasal Sinus Ostia: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg, 2018, 144(1): 28-35

[13] KennedyDW. The PROPEL™ steroid-releasing bioabsorbable implant to improve outcomes of sinus surgery. Expert Rev Respir Med, 2012, 6(5): 493-498

[14] Huang Z, Zhou B, Wang D, et al. Comparison of Bioabsorbable Steroid-Eluting Sinus Stents Versus Nasopore After Endoscopic Sinus Surgery:A Multicenter, Randomized, Controlled, Single-Blinded Clinical Trial. Ear Nose Throat J, 2020,145561320947632

[15] ForwithKD, ChandraRK, YunPT, et al.. ADVANCE: a multisite trial of bioabsorbable steroid-eluting sinus implants. Laryngoscope, 2011, 121(11): 2473-2480

[16] GoshtasbiK, AbouzariM, AbiriA, et al.. Efficacy of steroid-eluting stents in management of chronic rhinosinusitis after endoscopic sinus surgery: updated meta-analysis. Int Forum Allergy Rhinol, 2019, 9(12): 1443-1450

[17] HongH, WangD, TanKS, et al.. Sinus computed tomography predicts clinical response to corticosteroids in chronic rhinosinusitis with nasal polyps. Clin Transl Allergy, 2018, 8: 24

[18] EppersonMV, PhillipsKM, CaradonnaDS, et al.. Predictors of efficacy for combination oral and topical corticosteroids to treat patients with chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol, 2019, 9(12): 1436-1442

[19] ReddelHK, BatemanED, BeckerA, et al.. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J, 2015, 46(3): 622-639

[20] HuY, CaoPP, LiangGT, et al.. Diagnostic significance of blood eosinophil count in eosinophilic chronic rhinosinusitis with nasal polyps in Chinese adults. Laryngoscope, 2012, 122(3): 498-503

[21] TajudeenBA, GantiA, KuharHN, et al.. The presence of eosinophil aggregates correlates with increased postoperative prednisone requirement. Laryngoscope, 2019, 129(4): 794-799

[22] XuG, JiangH, LiH, et al.. Stages of nasal mucosal transitional course after functional endoscopic sinus surgery and their clinical indications. ORL J Otorhinolaryngol Relat Spec, 2008, 70(2): 118-123

[23] GurrolaJ2nd, BorishL. Chronic rhinosinusitis: Endotypes, biomarkers, and treatment response. J Allergy Clin Immunol, 2017, 140(6): 1499-1508

[24] SellaGCP, TamashiroE, SellaJA, et al.. Asthma Is the Dominant Factor for Recurrence in Chronic Rhinosinusitis. J Allergy Clin Immunol Pract, 2020, 8(1): 302-309

[25] BaiJ, HuangJH, PriceCPE, et al.. Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol, 2022, 150(2): 352-361.e357

[26] LiaoB, LiuJX, LiZY, et al.. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy, 2018, 73(7): 1459-1469

[27] TomassenP, VandeplasG, Van ZeleT, et al.. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol, 2016, 137(5): 1449-1456.e1444

[28] LaidlawTM, MullolJ, WoessnerKM, et al.. Chronic Rhinosinusitis with Nasal Polyps and Asthma. J Allergy Clin Immunol Pract, 2021, 9(3): 1133-1141

[29] de Borja CallejasF, Martínez-AntónA, PicadoC, et al.. Corticosteroid treatment regulates mucosal remodeling in chronic rhinosinusitis with nasal polyps. Laryngoscope, 2015, 125(5): E158-E167

[30] JinM, WatkinsS, LarribaY, et al.. Real-time imaging of asthmatic epithelial cells identifies migratory deficiencies under type-2 conditions. J Allergy Clin Immunol, 2022, 149(2): 579-588

[31] ZengM, WangH, LiaoB, et al.. Clinical and Biological Markers Predict the Efficacy of Glucocorticoid- and Macrolide-Based Postoperative Therapy in Patients With Chronic Rhinosinusitis. Am J Rhinol Allergy, 2021, 35(5): 596-606

[32] VentoSI, BlomgrenK, HytönenM, et al.. Prevention of relapses of nasal polyposis with intranasal triamcinolone acetonide after polyp surgery: a prospective double-blind, placebo-controlled, randomised study with a 9-month follow-up. Clin Otolaryngol, 2012, 37(2): 117-123

[33] De CorsoE, SettimiS, TricaricoL, et al.. Predictors of Disease Control After Endoscopic Sinus Surgery Plus Long-Term Local Corticosteroids in CRSwNP. Am J Rhinol Allergy, 2021, 35(1): 77-85

[34] MukherjeeM, SvenningsenS, NairP. Glucocortiosteroid subsensitivity and asthma severity. Curr Opin Pulm Med, 2017, 23(1): 78-88

[35] FahyJV. Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol, 2015, 15(1): 57-65

[36] FanY, ChenS, QuX, et al.. A lower prevalence of asthma among patients with chronic rhinosinusitis in southern China. J Allergy Clin Immunol, 2011, 127(2): 520–522.e521-e525